Credit Suisse Ag Atreca, Inc. Transaction History

Credit Suisse Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$1.56 - $3.25 $21 - $45	14 New	14 $0
Q4 2021 Feb 14, 2022	SELL	$2.87 - $6.29 $53,247 - $116,698	-18,553 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $1,252 - $2,312	255 Added 1.39%	18,553 $115,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $6,819 - $12,033	-872 Reduced 4.55%	18,298 $156,000
Q1 2021 May 14, 2021	SELL	$13.0 - $19.34 $341,536 - $508,100	-26,272 Reduced 57.81%	19,170 $294,000
Q4 2020 Feb 12, 2021	BUY	$13.03 - $17.09 $292,771 - $383,995	22,469 Added 97.81%	45,442 $733,000
Q3 2020 Nov 13, 2020	BUY	$12.67 - $23.19 $291,067 - $532,743	22,973 New	22,973 $321,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.